IMRIS completes $20.7 million equity financing
Proceeds of the offering will be used for working capital and general corporate and administrative purposes.
IMRIS (TSX: IM) is a global leader in providing fully integrated, advanced imaging solutions that incorporate multiple imaging modalities including magnetic resonance and fluoroscopy to deliver timely information to clinicians during surgical or interventional procedures. The Company's systems utilize patented technology that allows a high field MR scanner to be moved in to the operating room on demand, providing imaging during the surgical or interventional procedure without compromising patient safety. The Company's flagship product, IMRISneuro, has been validated by leading neurosurgeons and is in use at neuroscience centers around the world.
Forward Looking Statements
This press release contains forward-looking statements that involve risks, uncertainties and assumptions. Such statements are only predictions, and the Company's actual financial conditions and results of operations could differ materially from those that may be contemplated by these forward looking statements and the assumptions upon which they are based as a result of those risks and uncertainties including risks related to the use of proceeds from the offering. For a discussion of important factors affecting the Company, see the "NARRATIVE DESCRIPTION OF THE BUSINESS" and in particular the subsection entitled "Risks Related to Our Business" in the Company's Annual Information Form filed on SEDAR and available at http://www.sedar.com.For further information: Brad Woods, Director Investor Relations & Corporate Communications, IMRIS Inc., Tel: (204) 480-7094, Email: email@example.com